Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

INTRODUCTION: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse events (AEs) remains unknown. METHODS: Patients with stage III NSLCC treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaverdian, Narek, Offin, Michael, Shepherd, Annemarie F., Hellmann, Matthew D., Gomez, Daniel R., Chaft, Jamie E., Rimner, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474390/
https://www.ncbi.nlm.nih.gov/pubmed/34590042
http://dx.doi.org/10.1016/j.jtocrr.2021.100197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474390/
https://www.ncbi.nlm.nih.gov/pubmed/34590042
http://dx.doi.org/10.1016/j.jtocrr.2021.100197

Ejemplares similares